Memini

Memantine Hydrochloride, the active ingredient in Memini, is a NMDA receptor antagonist presented as an oral tablet for oral use. It is indicated for the treatment of moderate to severe Alzheimer's disease in adults. GNH USA supplies Memini as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Memini is used in the management of Alzheimer's disease, acting on glutamatergic neurotransmission to help preserve cognitive function. - Alzheimer's disease (moderate to severe): may improve cognition and daily functioning. - Alzheimer's disease (mild to moderate) as adjunct therapy: can provide additional benefit when combined with cholinesterase inhibitors. - Behavioral symptoms in Alzheimer's disease: may reduce agitation and improve patient cooperation.

Common Side Effects: - Dizziness: mild to moderate sensation of light‑headedness. - Headache: transient cranial discomfort. - Constipation: reduced bowel movements. - Confusion: temporary mental clouding. - Fatigue: increased tiredness. - Hypertension: elevated blood pressure readings.

Serious or Rare Side Effects: - Seizures: convulsive episodes requiring immediate medical attention. - Cardiac arrhythmia: irregular heart rhythm potentially serious. - Severe allergic reaction: rash, swelling, or difficulty breathing. - Stevens‑Johnson syndrome: rare skin disorder with blistering.

Memini should be used with caution in specific clinical situations. - Renal impairment: assess kidney function and adjust therapy if needed. - Hepatic impairment: monitor liver enzymes during treatment. - History of seizures: evaluate risk and consider alternative therapy. - Concurrent NMDA antagonists: avoid combined use to prevent additive neurotoxicity. - Pregnancy and lactation: safety not established; use only if benefits outweigh risks. - Store at ambient temperature below 25°C: keep in original packaging, protect from moisture.

Memini may interact with several medicines; monitoring is advised. Major Interactions (Avoid): - Amantadine: additive NMDA antagonism may increase neurotoxicity. - Other NMDA antagonists (e.g., ketamine): heightened risk of central nervous system effects. - Strong CYP450 inducers (e.g., carbamazepine): may lower memantine plasma concentrations. - Anticholinergic agents: can worsen cognitive impairment. Moderate Interactions (Monitor Closely): - Diuretics: may enhance hypotensive effects. - Antihypertensives: monitor blood pressure for additive lowering. - Anticholinesterase inhibitors: observe for changes in therapeutic response.